Solbinsiran vs SYH2070
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: ANGPTL3 · full Atherosclerotic Cardiovascular Disease pipeline
Solbinsiran
Developed by Eli Lilly
NCT05256654 · Phase 2 · completed
The study randomized 205 participants to three solbinsiran doses or placebo and masked both participants and investigators. Its primary endpoint was a laboratory biomarker rather than a hard clinical outcome, and the ApoB comparison was mixed across doses: significant for 400 mg but not for 100 mg or 800 mg, supporting moderate evidence rather than the highest grade.
Next expected readout: March 2027 · NCT07269210 (registry estimate)
Reported efficacy
Percent Change From Baseline for Apolipoprotein B (ApoB) at Day 180 (Baseline, Day 180): Percent Change From Baseline for Apolipoprotein B (ApoB) at Day 180 (Baseline, Day 180): LY3561774 100 mg -14.1% (Standard Error 4.98) | LY3561774 400 mg -24.3% (Standard Error 3.1) | LY3561774 800 mg -19% (Standard Error 3.35) vs Placebo -11.6% (Standard Error 3.65) (mixed)
Result source: NCT05256654
SYH2070
Developed by CSPC Pharmaceutical Group
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: April 2027 · NCT07695597 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Solbinsiran | SYH2070 |
|---|---|---|
| LDL-C, % change | -17.5% vs -12.7%−4.8 vs placeboNCT052566545 other results
| —Not reported |
| Non-HDL-C, % change | -27.3% vs -9.8%−17.5 vs placeboNCT052566545 other results
| —Not reported |
| ApoB, % change | -19% vs -11.6%−7.4 vs placeboNCT052566545 other results
| —Not reported |
| Lp(a), % change | —Not reported | —Not reported |
| 3-point MACE (% with event) | —Not reported | —Not reported |
LDL-C, % change
- Solbinsiran
- -17.5% vs -12.7%−4.8 vs placeboNCT05256654
5 other results
- -19.7% vs -8.7% NCT05256654
- -21% vs -12.7% NCT05256654
- -24% vs -8.7% NCT05256654
- -7.1% vs -12.7% NCT05256654
- -9.9% vs -8.7% NCT05256654
- SYH2070
- —Not reported
Non-HDL-C, % change
- Solbinsiran
- -27.3% vs -9.8%−17.5 vs placeboNCT05256654
5 other results
- -31.5% vs -10.2% NCT05256654
- -27.6% vs -9.8% NCT05256654
- -33.1% vs -10.2% NCT05256654
- -13.5% vs -9.8% NCT05256654
- -19.8% vs -10.2% NCT05256654
- SYH2070
- —Not reported
ApoB, % change
- Solbinsiran
- -19% vs -11.6%−7.4 vs placeboNCT05256654
5 other results
- -24.3% vs -11.6% NCT05256654
- -14.1% vs -11.6% NCT05256654
- -19.4% vs -9.5% NCT05256654
- -19.7% vs -9.5% NCT05256654
- -19.2% vs -9.5% NCT05256654
- SYH2070
- —Not reported
Lp(a), % change
- Solbinsiran
- —Not reported
- SYH2070
- —Not reported
3-point MACE (% with event)
- Solbinsiran
- —Not reported
- SYH2070
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
SYH2070: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Solbinsiran: 4 of 4 rows · SYH2070: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Solbinsiran |
|---|---|
| Dropout rate | 8.5%800 mg NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2 show 2 more results5.2%400 mg NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2 10%100 mg NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2 |
| Discontinued due to AEs | 0%800 mg NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2 show 2 more results1.7%400 mg NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2 0%100 mg NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2 |
| Serious AEs | 3.4%800 mg NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2 show 2 more results5.2%400 mg NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2 3.3%100 mg NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2 |
| Most frequent reported AEs | 800 mg covid-19 3.4% (placebo 7%) hypertension 3.4% (placebo 3.5%) influenza 3.4% (placebo 0%) NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2 show 2 more results400 mg covid-19 5.2% (placebo 7%) injection site reaction 5.2% (placebo 0%) nasopharyngitis 5.2% (placebo 5.3%) NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2 100 mg covid-19 13.3% (placebo 7%) gastroenteritis 10% (placebo 5.3%) hypertension 6.7% (placebo 3.5%) NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Solbinsiran
show 5 more results
show 5 more results
show 5 more results
show 5 more results
show 5 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Solbinsiran's landscape · SYH2070's landscape